We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

170 hedge funds and large institutions have $1.32B invested in Viridian Therapeutics in 2025 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 62 increasing their positions, 64 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding in top 10

Funds holding in top 10: 8 → 10 (+2)

7% more capital invested

Capital invested by funds: $1.23B → $1.32B (+$90.3M)

3.77% more ownership

Funds ownership: 112.12% → 115.89% (+3.8%)

3% less repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 64

3% less funds holding

Funds holding: 176 → 170 (-6)

21% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 28

70% less call options, than puts

Call options by funds: $1.81M | Put options by funds: $5.96M

Holders
170
Holders Change
-6
Holders Change %
-3.41%
% of All Funds
2.24%
Holding in Top 10
10
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+25%
% of All Funds
0.13%
New
22
Increased
62
Reduced
64
Closed
28
Calls
$1.81M
Puts
$5.96M
Net Calls
-$4.15M
Net Calls Change
-$5.06M

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$23.7M
2
CC
Commodore Capital
New York
+$17.3M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$16.4M
4
PBA
Paradigm Biocapital Advisors
New York
+$8.77M
5
Citadel Advisors
Citadel Advisors
Florida
+$7.61M

Top Sellers

Rank Fund Capital Flow
1
DCM
Driehaus Capital Management
Illinois
-$12.1M
2
GPP
Great Point Partners
Connecticut
-$10.1M
3
OCA
Octagon Capital Advisors
New York
-$6.07M
4
Goldman Sachs
Goldman Sachs
New York
-$4.5M
5
Renaissance Technologies
Renaissance Technologies
New York
-$4.32M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
26
Candriam SCA
Luxembourg
$12.1M -$246K -18,157 -2%
WP
27
Woodline Partners
California
$11.4M +$24.9K +1,838 +0.2%
5VM
28
5AM Venture Management
California
$10.3M – – –
RA
29
Rosalind Advisors
Ontario, Canada
$9.79M +$1.43M +105,000 +18%
Citadel Advisors
30
Citadel Advisors
Florida
$9.08M +$7.61M +560,996 +634%
Northern Trust
31
Northern Trust
Illinois
$8.34M -$1.43M -105,634 -15%
Charles Schwab
32
Charles Schwab
California
$8.02M +$109K +8,058 +1%
Victory Capital Management
33
Victory Capital Management
Texas
$7.9M +$162K +11,940 +2%
UBS Group
34
UBS Group
Switzerland
$7.46M +$400K +29,458 +6%
RHJA
35
Rice Hall James & Associates
California
$7.21M +$2.07M +152,730 +42%
Fisher Asset Management
36
Fisher Asset Management
Washington
$7.13M -$367K -27,065 -5%
YCM
37
Yiheng Capital Management
California
$6.99M – – –
Dimensional Fund Advisors
38
Dimensional Fund Advisors
Texas
$6.79M +$6.59M +485,698 New
HS
39
HighVista Strategies
Massachusetts
$6.77M +$4.13M +304,008 +168%
IC
40
Ikarian Capital
Texas
$6.57M -$339K -25,000 -5%
PA
41
Perceptive Advisors
New York
$6.26M -$2.88M -212,155 -32%
NNPTE
42
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne
Poland
$5.92M – – –
JP Morgan Chase
43
JP Morgan Chase
New York
$5.82M +$1.59M +117,439 +39%
AAA
44
Affinity Asset Advisors
New York
$5.45M – – –
Deutsche Bank
45
Deutsche Bank
Germany
$5.41M -$134K -9,870 -2%
DCM
46
Driehaus Capital Management
Illinois
$5.27M -$12.1M -893,635 -70%
PAM
47
Panagora Asset Management
Massachusetts
$4.92M -$39.2K -2,887 -0.8%
Royal Bank of Canada
48
Royal Bank of Canada
Ontario, Canada
$4.83M +$4.69M +345,685 +162,293%
Raymond James Financial
49
Raymond James Financial
Florida
$4.64M +$188K +13,849 +4%
Wellington Management Group
50
Wellington Management Group
Massachusetts
$3.78M +$290K +21,373 +9%
1
2
3 4 5

VRDN Hedge Fund Activity: Q2 2025 in Review

170 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q2 2025, worth a combined $1.32B — up 7.3% from $1.23B a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of VRDN and 22 opened new positions — a net loss of 6 holders — while 64 trimmed existing stakes and 62 added.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $23.7M. The largest seller was Driehaus Capital Management, cutting an estimated $12.1M.

  • 170 institutional investors held Viridian Therapeutics (VRDN) as of Q2 2025, down from 176 in Q1 2025.
  • Funds reported $1.32B of Viridian Therapeutics stock for Q2 2025, up 7.3% quarter-over-quarter.
  • 22 funds opened new Viridian Therapeutics positions in Q2 2025 and 28 closed out, a net change of -6 holders.
  • The largest Viridian Therapeutics buyer in Q2 2025 was Baker Bros. Advisors, an estimated $23.7M added.
  • The largest Viridian Therapeutics seller in Q2 2025 was Driehaus Capital Management, an estimated $12.1M sold.

Based on aggregated 13F filings for Q2 2025.